TP53 and dry eye syndrome: Specifically, CF@SNPs attenuate dry eye pathology by suppressing p53‐SLC7A11‐GSH‐dependent ferroptosis and TNF‐α‐associated inflammatory cascades, accompanied by favorable biocompatibility in vivo.